Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeutic assets.
Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that The University of Alabama’s Culverhouse College of Business will continue its participation in the ai² Pipeline division for the upcoming academic year. The renewed collaboration extends a hands-on program in which students evaluate real-world biopharmaceutical business development and asset assessment opportunities. The program also supports Lōkahi’s strategy of identifying and evaluating promising therapeutic assets that may have been overlooked or are no longer being actively developed.
Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced a collaboration with San Diego State University's (SDSU) Fowler College of Business, expanding the ai² Futures Lab™ and strengthening Lōkahi’s growing network of partner academic institutions. The partnership with SDSU furthers Lōkahi’s work to identify and evaluate promising drug candidates and technologies that may have been overlooked or are no longer being actively developed. The program also supports Lōkahi’s efforts to explore potential new treatments while giving student participants practical experience addressing business challenges in the biopharmaceutical industry.
Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai² Futures Lab™. The renewed collaboration expands Lōkahi’s growing nationwide network of academic institutions contributing to the identification and evaluation of underdeveloped, overlooked, or strategically deprioritized therapeutic assets. The program functions as a capital-efficient component of Lōkahi’s asset origination and evaluation process while providing students with direct experience addressing real-world biopharmaceutical business challenges.
Lōkahi Therapeutics Welcomes the Student Industry Fellows Program at the University of Georgia to the ai² Futures Lab™ Program
Lōkahi Therapeutics today announced the participation of the University of Georgia’s Student Industry Fellows Program in its ai² (actual intelligence) Futures Lab program for the Spring 2026 semester. Through this collaboration, University of Georgia students will engage in applied, real-world biotech and life sciences projects designed to bridge academic learning with industry execution.
